Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS

被引：2
|
作者：
Murphy, Tracy
Leber, Brian
Bray, Mark R.
Chan, Steven M.
Gupta, Vikas
Khalaf, Dina
Maze, Dawn
McNamara, Caroline J.
Schimmer, Aaron D.
Schuh, Andre C.
Sibai, Hassan
Fletcher, Graham
Valiquette, Debbie
Martin, Kylie
Minden, Mark D.
Yee, Karen W. L.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-138822
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
    Richard-Carpentier, Guillaume
    DeZern, Amy E.
    Takahashi, Koichi
    Konopleva, Marina Y.
    Loghavi, Sanam
    Masarova, Lucia
    Alvarado, Yesid
    Ravandi, Farhad
    Bravo, Guillermo Montalban
    Naqvi, Kiran
    Sasaki, Koji
    Delumpa, Ricardo
    Kwari, Monica
    Sekeres, Mikkael A.
    Nazha, Aziz
    Roboz, Gail J.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    DiNardo, Courtney D.
    BLOOD, 2019, 134
  • [22] Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies
    Talpaz, M.
    Shah, N. P.
    Deininger, M. W.
    Mauro, M. J.
    Flinn, I. W.
    Lustgarten, S.
    Lindmark, W.
    Gozgit, J. M.
    Clackson, T.
    Turner, C. D.
    Haluska, F. G.
    Kantarjian, H.
    Cortes, J. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results
    Assouline, Sarit
    Miggiano, Maria Cristina
    Abruzzese, Elisabetta
    Elena, Chiara
    Caocci, Giovanni
    Saussele, Susanne
    Lunghi, Francesca
    Alvarez-Larran, Alberto
    Mora, Barbara
    Petrela, Sigi
    Antolini, Laura
    Gambacorti-Passerini, Carlo
    Iurlo, Alessandra
    BLOOD, 2021, 138
  • [24] Preliminary Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)
    Pratz, Keith
    Cherry, Mohamad
    Altman, Jessica K.
    Cooper, Brenda W.
    Cruz, Jose Carlos
    Jurcic, Joseph G.
    Levis, Mark J.
    Lin, Tara L.
    Perl, Alexander E.
    Podoltsev, Nikolai A.
    Schiller, Gary J.
    Liu, Chaofeng
    Bahceci, Erkut
    BLOOD, 2017, 130
  • [25] A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia
    Cahill, Kirk E.
    Karimi, Yasmin H.
    Karrison, Theodore G.
    Jain, Nitin
    Green, Margaret
    Weiner, Howard
    Fulton, Noreen
    Kadri, Sabah
    Godley, Lucy A.
    Artz, Andrew S.
    Liu, Hongtao
    Thirman, Michael J.
    Le Beau, Michelle M.
    McNerney, Megan E.
    Segal, Jeremy
    Larson, Richard A.
    Stock, Wendy
    Odenike, Olatoyosi
    BLOOD ADVANCES, 2020, 4 (04) : 599 - 606
  • [26] A phase I study of busulfan consolidation/intensification therapy for patients with high risk acute myeloid leukemia (AML).
    Gharibo, M. M.
    Schaar, D.
    Rubin, A.
    Grospe, S.
    Dudek, L.
    Strair, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 356S - 356S
  • [27] PHASE I/II STUDY OF VOSAROXIN AND DECITABINE IN NEWLY DIAGNOSED OLDER PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
    Daver, N.
    Kantarjian, H.
    Garcia-Manero, G.
    Jabbour, E.
    Borthakur, G.
    Pierce, S.
    Vaughan, K.
    Vaughan, K.
    Ning, J.
    Gonzalez, G.
    Pemmarjau, N.
    Kadia, T.
    Konopleva, M.
    Andreeff, M.
    DiNardo, C.
    Cortes, J.
    Ward, R.
    Craig, A.
    Ravandi, F.
    HAEMATOLOGICA, 2016, 101 : 187 - 188
  • [28] Optimal dosing of a novel PLK4 inhibitor nested in a phase II study of CFI-400945 in patients with Advanced/Metastatic Breast Cancer (MBC): Canadian Cancer Trials Group (CCTG) IND.237
    Rushton, M.
    Cescon, D.
    Hilton, J.
    Bedard, P.
    Blanchette, P.
    Bashir, A.
    Pezo, R.
    Kumar, V.
    Ng, T.
    Awan, A.
    Lott, A.
    Raphael, J. A.
    Hagerman, L.
    Bray, M.
    Muyot, L.
    Antras, J. Fuentes
    Seymour, L.
    Tu, D.
    Gaudreau, P. O.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S31 - S31
  • [29] Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)
    Wei, Andrew H.
    Breccia, Massimo
    Ooi, Melissa
    Romero, Maria Teresa Cedena
    Ciceri, Fabio
    Erba, Harry P.
    Gaur, Anil
    Sechaud, Romain
    Halilovic, Ensar
    Kuenzle, Brigitte
    Fabre, Claire
    Porkka, Kimmo
    BLOOD, 2021, 138
  • [30] Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
    Assi, Rita
    Kantarjian, Hagop M.
    Daver, Naval G.
    Garcia-Manero, Guillermo
    Benton, Christopher B.
    Thompson, Philip A.
    Borthakur, Gautam
    Kadia, Tapan M.
    Alvarado, Yesid
    Jabbour, Elias J.
    Konopleva, Marina Y.
    Takahashi, Koichi
    Kornblau, Steven M.
    DiNardo, Courtney D.
    Estrov, Zeev E.
    Flores, Wilmer
    Basu, Sreyashi
    Allison, James P.
    Sharma, Padmanee
    Pierce, Sherry A.
    Pike, Allison
    Cortes, Jorge E.
    Ravandi, Farhad
    BLOOD, 2018, 132
12345